Flat ₹100 OFF on First app order | Use Code: APP100 |
Flat ₹100 OFF
on First app order
Use Code
APP100
Download Now
Top Brand
Salt CompositionGefitinib 250mg
Our Recommendation
Geftinat 250mg Tablet 30s
2,056+ trust this
WHO GMP Certified
2,056+ trust this
WHO GMP Certified
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
Delivery by
Used In
Non-small cell lung cancer
Customers also bought
More About Geftinat
Benefits
In Non-small cell lung cancer Non-small cell lung cancer is one of the major kinds of lung cancer and it affects both smokers as well as non-smokers. Geftinat 250mg Tablet helps treat non-small cell lung cancer and may be given alone or in combination with other medicines. It is a potent and very toxic medicine and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated.
Side Effects
The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you're worried about them.
How to use
Follow your doctor's guidance regarding the dose and duration of this medication. Ingest it without breaking or crushing. Do not chew, crush or break it. Geftinat 250mg Tablet can be taken it with or without food, although it's advisable to take it consistently at the same time.
How it works
Geftinat 250mg Tablet is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.
Unsafe: Avoid consuming alcohol with Geftinat 250mg Tablet as it is deemed unsafe.
Seek medical advice from your doctor: Geftinat 250mg Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Doctor consultation is advised.
Seek medical advice from your doctor: Geftinat 250mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Not Safe: Geftinat 250mg Tablet may cause side effects which could affect your ability to drive. Geftinat 250mg Tablet may make you feel weak. This may affect your driving ability.
Caution Advised: Geftinat 250mg Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Geftinat 250mg Tablet may be needed. Doctor consultation is advised.
Safe when prescribed by an expert: Geftinat 250mg Tablet is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Geftinat 250mg Tablet may not be needed in these patients. Doctor consultation is advised.
What if I forget to take it?
If you forget a dose of Geftinat 250mg Tablet , simply continue with your regular schedule and do not take a double dose.
Manufacturer Address
Natco House, Road No.2, Banjara Hills, Hyderabad-500 034, India
References
Chabner BA, Barnes J, Neal J, et al. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilmans: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1734-35
Chu E, Sartorelli AC. Cancer Chemotherapy. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. pp. 954-55
Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 616-17
Gefitinib. Luton, Bedfordshire: AstraZeneca UK Limited; 2009 (232 Jan. 2019)
Drugs and Lactation Database (LactMed) (18 Feb. 2020)
Central Drugs Standard Control Organisation (CDSCO) (27 Mar. 2019)
CiplaMed. Gefitinib (06 Apr. 2024)
Disclaimer
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.